SCYNEXIS to Present Two Ibrexafungerp (Brexafemmeᵀᴹ) Posters at the 2021 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting JERSEY CITY, N.J., April 20, 2021 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections,...
Category: News
Nabriva Commences Exclusive Distribution of SIVEXTRO® (tedizolid phosphate) in the U.S.
– SIVEXTRO now available under Nabriva’s National Drug Code – 100% of SIVEXTRO’s net product sales to be recorded by Nabriva DUBLIN, Ireland and FORT WASHINGTON, Pa., April 15, 2021 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections,...
Creating a network of authentic relationships to best serve patients
A patient might be in touch with the physician, the physician’s office, and the pharmacy. But, behind the scenes, our key account managers are working to ensure the patient-serving process runs smoothly. For Taylor Lenz, key account manager in Las Vegas, Nevada, that means creating authentic relationships with providers and pharmacies to provide innovative solutions....
Leading the way for a new standard of care
A podiatrist in Georgia heard this from a patient with a severe heel infection. Many patients at this wound care clinic were already reluctant to check into a hospital for a several-day stay to receive a series of IV treatments. But now during the COVID-19 pandemic, patients are refusing. This patient’s infection was so severe...
When the pandemic struck, here’s how our team made a life-saving impact
The U.S. was in lockdown for the COVID-19 pandemic. The healthcare space was in crisis. Our team was navigating the new work-from-home reality. Amidst the world upheaval, one thing was top of mind for our Sunbelt sales team — they wanted to make a positive impact in their communities. “We make a life-saving impact every...
Cidara Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will present a corporate overview at the 20th Annual Needham Virtual...
Iterum Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
DUBLIN, Ireland and CHICAGO, April 06, 2021 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that Corey Fishman, Chief Executive...
Cidara Therapeutics Announces Agreement with Janssen to Develop and Commercialize AVCs for the Prevention and Treatment of Influenza
Collaboration includes exclusive worldwide rights to Cidara’s CD388 and other influenza Antiviral Conjugates (AVCs) for up to $780 million in upfront, milestone payments and R&D funding Cidara to advance CD388 through Phase 2 development funded by Janssen Conference call and webcast today at 8:30 AM Eastern Time SAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) —...
Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland, April 02, 2021 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted non-statutory stock options to purchase an aggregate of 106,000 ordinary shares of Nabriva Therapeutics as an inducement to two...
Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, April 01, 2021 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that the Compensation Committee of its Board of Directors granted non-qualified stock option awards and restricted stock units for an aggregate of 27,000...